Publications by authors named "Jieren Luo"
Article Synopsis
- The study evaluates the effectiveness of various drugs and a placebo in treating primary progressive multiple sclerosis (PPMS) through a quantitative analysis of existing clinical trials.
- A total of 15 studies with 3779 patients were analyzed, identifying 12 drugs; while some drugs showed similar efficacy to placebo, others, particularly ocrelizumab, demonstrated significantly better outcomes.
- The findings contribute valuable data for informed clinical decisions regarding PPMS treatment and guide future clinical research.
Objective: While platelet rich plasma (PRP) has been extensively studied in treating osteoarthritis (OA), there has been an ongoing debate regarding the efficacy of PRP and the optimal subpopulation for PRP treatment remains unknown. The authors hereby aim to establish a pharmacodynamic model-based meta-analysis to quantitatively evaluate PRP efficacy, comparing with hyaluronic acid (HA) and identify relevant factors that significantly affect the efficacy of PRP treatment for OA.
Methods: The authors searched for PubMed and the Cochrane Library Central Register of Controlled Trials of PRP randomized controlled trials (RCTs) for the treatment of symptomatic or radiographic OA from the inception dates to 15 July 2022.
Importance: In osteoarthritis (OA) clinical trials, a placebo is often used as control. Therefore, a thorough understanding of the placebo response is important for guiding drug development in OA.
Objective: To develop an oral placebo response model for OA.
Article Synopsis
- Neuromyelitis optica spectrum disorders (NMOSD) is a disease that affects the central nervous system and this study compared seven different drugs to see which one is most effective at preventing relapses.
- A total of 24 clinical trials involving 2207 patients were analyzed, focusing on the "time to first relapse" after treatment to determine the long-term effects of each drug.
- The results indicated that eculizumab was the most effective, with 98.9% of patients remaining relapse-free at 24 months, providing valuable data for future clinical practice and research.
Introduction: There is a wide variety of drugs for the clinical treatment of immunoglobulin A (IgA) nephropathy; however, previous studies have failed to clarify the quantitative differences in the efficacy of various drugs. In this study, we aimed to quantitatively compare the clinical efficacy of 6 classes of drugs with different pharmacological mechanisms for the treatment of IgA nephropathy and to identify relevant influencing factors.
Methods: Clinical trials of drugs for the treatment of IgA nephropathy were obtained from public databases.